LAMIVUDINE,NEVIRAPINE,TENOFOVIR DISOPROXIL FUMARATE

Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate are antiviral medications containing these active ingredients. They are indicated for the treatment of Human Immunodeficiency Virus (HIV-1) and Hepatitis B virus infections in adults. These antiviral medications delay complications associated with AIDS and improve overall quality of life. They work to suppress HIV reproduction for as long as possible. Lamivudine received FDA approval for HIV treatment in November 1995. Nevirapine received FDA approval for HIV treatment in June 1996. Tenofovir disoproxil fumarate received FDA approval for HIV treatment in October 2001.

Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate are used for HIV-1 Infection and Hepatitis B Infection

To consume Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate, follow your healthcare provider'sprovider's instructions regarding dosage, frequency, and duration. Take it with or without food, swallowing the tablets or capsules with water. Adhere to the prescribed dosing schedule; do not alter the dosage without consulting your healthcare provider.

Side effects of the medications Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate may include but are not limited to nausea, vomiting, diarrhea, headache, fatigue, dizziness, rash, liver toxicity, changes in kidney function, bone loss, increased risk of fractures, changes in cholesterol or blood sugar levels, and potential drug interactions.

Using Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate carries several warnings. These include the risk of hepatotoxicity (liver toxicity), hypersensitivity reactions, lactic acidosis, immune reconstitution syndrome (antiviral drug causes worsening of previous infection present in the body), bone loss, and renal impairment associated with tenofovir, potential immune system changes, the risk of developing drug resistance, renal impairment, pancreatitis, changes in body fat distribution, and possible mental health effects.

Precautions for these medications include monitoring liver function, particularly in individuals with pre-existing liver disease. Signs of severe hypersensitivity reactions or liver toxicity should be closely watched for. The potential risk of lactic acidosis, especially in those with predisposing factors, should be considered. Regular bone density and renal function monitoring is advised for individuals taking Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate.

Before taking Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate, you should be aware of the potential risks and warnings. Pregnant and breastfeeding women must consult their doctor before use. Use with caution if you have pre-existing conditions affecting the liver, kidney, pancreas, or bone, as this combination may worsen them. Regular blood examination and monitoring of blood glucose levels are recommended during treatment. Close monitoring and appropriate management are necessary in such cases. Consult your physician if you have a heart condition or electrolyte imbalance. Inform your physician before starting treatment if you have or have had mental illness, seizures, Hepatitis infection, skin rashes, or any other signs of infection or inflammation. Adherence to these precautions, regular monitoring, and ongoing communication with your healthcare provider help ensure safe and effective use.

Accord Healthcare Limited, Electronic Medicines Compendium (EMC), [Revised on Mar 2021] [Accessed on 20th May 2023], https://www.medicines.org.uk/emc/files/pil.8888.pdf Cipla (EU) Limited, Electronic Medicines Compendium (EMC), [Revised on Oct 2017] [Accessed on 20th May 2023], https://www.medicines.org.uk/emc/files/pil.10500.pdf KD Tripathi, Antiviral Drugs (Anti-retrovirus), Essentials of Medical Pharmacology, 8th Edition, 2019, 860-872 Sharon Safrin, Antiviral Agents, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 863-894